申请人:Japan Energy Corporation
公开号:US05821247A1
公开(公告)日:1998-10-13
Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group; R.sup.2 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group; R.sup.5 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group; P is a hydroxyl group; Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group; P may form together with Q an ether bond; R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group; X is a single bond, an --NR.sup.10 --group or a --CH.sub.2 --NR.sup.10 --group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group; Y is a methylene group or a carbonyl group; and dotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
本发明涉及一种羟基苯醌衍生物或其药学上可接受的盐,该羟基苯醌衍生物由公式(I)表示:##STR1##其中,R.sup.1是苯基,其未取代或被取代为取自卤原子、C1-4烷基和C1-4烷氧基的各自独立的取代基;R.sup.2是氢原子或C1-4烷基;R.sup.3和R.sup.4各自独立地是氢原子或C1-4烷基;R.sup.5是氢原子或C1-4烷基;R.sup.6,R.sup.7和R.sup.8各自独立地是氢原子或C1-4烷基;P是羟基;Q是羟基、C1-4烷氧基、C1-18酰氧基或氧代基;P可以与Q共同形成醚键;R是羟基、C1-4烷氧基、C1-18酰氧基或氧代基,但当Q和R中的一个为氧代基时,另一个也为氧代基;X是单键、--NR.sup.10--基团或--CH.sub.2--NR.sup.10--基团,其中R.sup.10是氢原子或C1-4烷基;Y是亚甲基基团或羰基基团;六元环中的点状键表示该六元环具有最大数量的双键。